What is Gliadel® Wafer?
GLIADEL® Wafer delivers BCNU directly to the site of the recurrent brain tumor. After a surgeon operates to remove GBM tissue, he or she implants up to eight dime-sized GLIADEL® Wafers in the space the tumor once occupied. Each wafer contains a precise amount of BCNU. Over the next 2 to 3 weeks, the wafers slowly dissolve, bathing the surrounding cells with BCNU. The goal of GLIADEL® Wafer therapy is to kill tumor cells left behind after surgery, thereby extending survival. (This was taken from the gliadel.com website with permission • Is GLIADEL® Wafer considered an experimental treatment? No. GLIADEL® Wafer is commercially available in the U.S. for the treatment of GBM. Originally, only for recurrent GBM, but it is now also approved for use at the time of the initial surgery. • Has GLIADEL® Wafer helped recurrent GBM patients live longer? Yes. LIADEL® Wafer has been shown to extend the lives of patients with recurrent GBM. According to one study, 56% of the GBM patients receiving GLI
